Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2022-09-29 AGM Information
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
2022 Annual General Meeting and Proxy Form 107 pages 1.1MB
AGM Information Classification · 100% confidence The document is an ASX announcement titled 'Notice of Annual General Meeting' for Living Cell Technologies Limited. It includes details about the date, time, and venue of the AGM, the agenda including resolutions to be voted on, information about proxy voting, and shareholder information. It references the financial report and remuneration report for the year ended 30 June 2022 but does not contain the reports themselves. The document is approximately 15,000 characters and is a formal notice to shareholders about the upcoming AGM and related voting matters. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting, specifically the notice and agenda for the meeting. It is not the Annual Report (10-K) or Remuneration Information (DEF 14A) itself, nor is it a voting results announcement (DVA).
2022-09-29 English
NEW 2022 Annual General Meeting Date 2 pages 179.3KB
AGM Information Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding a change in the date of their 2022 Annual General Meeting (AGM). It lists the proposed resolutions to be considered at the AGM, including director elections, ratification of share placements, amendments to the constitution, and director appointments and removals. The document is relatively short (4655 characters) and serves as a notice about the AGM date and agenda rather than the actual AGM materials or minutes. There is no detailed financial data, management discussion, or full report content. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, including announcements related to the meeting date and agenda.
2022-09-26 English
2022 Annual General Meeting Date 2 pages 177.7KB
AGM Information Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding the date and agenda of their 2022 Annual General Meeting (AGM). It includes details such as the meeting date, proposed resolutions including director re-elections, adoption of the remuneration report, and other shareholder matters. There is no detailed financial data, full report content, or transcript of the meeting itself. The document is short (4192 characters) and serves as a notice or announcement about the AGM rather than the AGM materials or minutes. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, specifically announcements related to the AGM.
2022-09-18 English
New milestone for LCT's AI development 3 pages 266.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited about a new milestone in advancing AI for the manufacture of NTCELL. It discusses progress in research and development, specifically the completion of the first stage of AI integration in manufacturing. The document includes forward-looking statements and references to previous ASX releases but does not contain financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. It is a corporate announcement about operational progress and research milestones rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2022-09-15 English
Receipt of Section 249D Notice 8 pages 343.8KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding the receipt of a Section 249D Notice under the Corporations Act 2001 (Cth). The notice is from a group of shareholders requesting the company to convene a general meeting to consider resolutions for the removal and appointment of directors. The document includes the text of the notice, the proposed resolutions, and execution statements from the shareholders. There is no financial data, earnings information, or report content. The document is clearly about changes in the company's board of directors and management. Therefore, it fits the category of Board/Management Information (MANG). The document length is over 12,000 characters, so it is not a brief announcement or a report publication announcement. It is a formal notice related to board changes.
2022-09-13 English
Becoming a substantial holder 11 pages 269.4KB
Major Shareholding Notification Classification · 95% confidence The document is a Form 603 under the Corporations Act 2001, titled 'Notice of initial substantial holder.' It details the substantial shareholding interests of several parties in Living Cell Technologies Limited, including voting power, relevant interests, and registered holders. It also includes annexures with notices to the board pursuant to sections 203D and 249D of the Corporations Act, which relate to requisitioning a general meeting and proposing resolutions to remove directors. The content is focused on notifying the market and regulators about a new substantial shareholder and their intentions regarding board composition. This type of filing is a Major Shareholding Notification, as it reports changes in significant share ownership levels and related corporate actions. It is not an annual report, earnings release, or management report, nor is it a proxy solicitation or voting results announcement. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and detail support a high confidence level.
2022-09-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.